
Join Christine Bangert, Mark Boguniewicz and Perla Lansang for an educational symposium on atopic dermatitis (AD) in children, exploring the diagnosis and pathophysiology of AD in children, the life-long effects of uncontrolled disease beyond the skin, and current and emerging therapies.

Review a patient case to learn more about identifying uncontrolled asthma and type 2 inflammation in pediatric patients

Dr. Amy Paller discusses the evolving concepts of early intervention and disease modification in AD and describes potential biomarkers of subclinical control at EADV 2025.

This video of the October 2024 ADVENT symposium at EAPS in Vienna, Austria features Drs Christine Bangert, Mark Boguniewicz, and Perla Lansang as they discuss the inflammatory processes driven by type 2 cytokines that lead to AD and atopic comorbidities, the multidimensional and cumulative disease burden associated with AD and its comorbidities, and the current and emerging treatment options for children with AD uncontrolled with topical therapy

Prof. Thomas Bieber explores early intervention and disease modification in atopic dermatitis.
Join ADVENT at the Digestive Disease Week 2024 Congress and visit the Sanofi and Regeneron Medical Booth # 1707.

Prof. Peter Hellings discusses the interconnection between the pathophysiology, burden and clinical management of uncontrolled and/or severe CRSwNP

Dr. Palomares discusses how type 2 inflammation, an aberrant immune response, underlies skin diseases like atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, linking to their clinical symptoms.

Explore 3 hypothetical patient cases using guideline-based checklists for assessment and diagnosis of type 2 inflammation in adult asthma

Prof. Claus Bachert describes how type 2 inflammation drives CRSwNP.

Inflammatory processes drive AD both within and beyond the skin, leading to significant, cumulative life impacts. Early intervention has the potential to mitigate these impacts by altering the disease course.

Prof. Peter Hellings describes how type 2 inflammation drives CRSwNP.